Lenvima 18 mg – DIN 02468239
Lenvima is Lenvatinib Mesylate 18 mg (capsule), sold in Canada. It is used for renal cell carcinoma and thyroid neoplasms. It is supplied by Eisai Limited. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Lenvatinib Mesylate 18 mg
- Brand
- Lenvima
- Strength
- 18 mg
- Used for
- Renal cell carcinoma and thyroid neoplasms
- Form
- Capsule
- Manufacturer
- Eisai Limited
- Drug class
- Cancer medicine (kinase inhibitor)
- Sold in
- Canada
- DIN
- 02468239
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Lenvatinib used for?
Lenvatinib is used for renal cell carcinoma and thyroid neoplasms.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
Differentiated Thyroid Cancer
LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Renal Cell Carcinoma
LENVIMA, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
LENVIMA, in combination with everolimus, is indicated for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.
Hepatocellular Carcinoma
LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Endometrial Carcinoma
LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
From the FDA-approved label on DailyMed (published Jun 30, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02468239.
- It names Lenvima, Lenvatinib Mesylate 18 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Lenvima each 18 mg daily dose contains 1 x 10 mg capsules and 2 x 4 mg capsules per blister by Eisai Limited.
In Canada: prescription only.
Ingredients
Active: Lenvatinib (Lenvatinib Mesylate)
Other Lenvatinib pills
- E LENV 10 mg Lenvatinib 10 mg Red & yellow, capsule, 14 mm Used for renal cell carcinoma and thyroid neoplasms
- E LENV 4 mg Lenvatinib 4 mg Red, capsule, 14 mm Used for renal cell carcinoma and thyroid neoplasms
- No picture yet DIN 02450321 Lenvatinib Mesylate 10 mg Lenvima, Capsule, sold in Canada Used for renal cell carcinoma and thyroid neoplasms
- No picture yet DIN 02484129 Lenvatinib Mesylate 12 mg Lenvima, Capsule, sold in Canada Used for renal cell carcinoma and thyroid neoplasms
- No picture yet DIN 02450313 Lenvatinib Mesylate 14 mg Lenvima, Capsule, sold in Canada Used for renal cell carcinoma and thyroid neoplasms
- No picture yet DIN 02450305 Lenvatinib Mesylate 20 mg Lenvima, Capsule, sold in Canada Used for renal cell carcinoma and thyroid neoplasms
- No picture yet DIN 02450291 Lenvatinib Mesylate 24 mg Lenvima, Capsule, sold in Canada Used for renal cell carcinoma and thyroid neoplasms
- No picture yet DIN 02484056 Lenvatinib Mesylate 4 mg Lenvima, Capsule, sold in Canada Used for renal cell carcinoma and thyroid neoplasms